| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6edb5285b39ab61950d1341a0eb9045f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate |
2020-04-08^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e556d1981ad03e234b6c6925000fed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a9b9d72b1a164440d62c424bf01834a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c7c60d8c358ae9da573785936e64ebb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e823ab3fe49118f15c2b9703ff151600
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0227b3e905c7deba39cb502bf9bbf20a |
| publicationDate |
2022-06-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11364249-B2 |
| titleOfInvention |
High-strength testosterone undecanoate compositions |
| abstract |
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided. |
| priorityDate |
2010-11-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |